Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shiga toxin 1 is a bacterial protein toxin produced by *Shigella dysenteriae* type 1 and Shiga toxin-producing *Escherichia coli* (STEC). It is an AB5-type holotoxin composed of one enzymatically active A subunit and a pentamer of B subunits. The B subunits bind to the cellular glycolipid globotriaosylceramide (Gb3) on host endothelial cells, facilitating endocytosis and retrograde trafficking to the endoplasmic reticulum. The A subunit then enters the cytosol and enzymatically removes a specific adenine from 28S rRNA, inactivating the ribosome and inhibiting protein synthesis, leading to cell death. Shiga toxin 1 is a major virulence factor in severe gastrointestinal infections, including hemorrhagic colitis and hemolytic uremic syndrome, particularly in children[1][2][3][6]. Key distinctions: Shiga toxin 1 is antigenically distinct from Shiga toxin 2 (Stx2). While both have similar mechanisms, Stx2 is generally more toxic in animal models and human disease. The primary clinical relevance of Shiga toxin 1 is as a virulence factor in infectious disease, making it a potential—but highly challenging—target for therapeutic intervention[1][3].
Ribosome inactivation by removing a specific adenine residue from the 28S rRNA of the 60S subunit, halting protein synthesis[1][3]. Cellular entry via binding B pentamer to the glycosphingolipid receptor globotriaosylceramide (Gb3)[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shiga toxin 1 (Stx1).